Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported two transactions in common stock. On May 13, 2026, she acquired 947 shares at no cost from performance-based restricted stock units earned after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified. On May 14, 2026, she sold 324 shares at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan to cover withholding tax from the PSU vesting, described as non-discretionary. Following these transactions, she directly owns 107,940 shares of Karyopharm common stock.
Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported a small set of routine equity transactions. On May 13, 2026, she acquired 121 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to completion of enrollment in the Company’s Phase 3 XPORT-EC-042 trial, which vested that day.
On May 14, 2026, 53 shares of common stock were sold at $9.50 per share in a broker-assisted transaction executed under a durable automatic sale instruction plan adopted on May 27, 2021, solely to satisfy withholding tax obligations from the PSU vesting, and not as a discretionary trade. After these transactions, Abate directly held 23,801 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported routine equity compensation activity. On May 13, 2026, he acquired 4,920 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to a Phase 3 XPORT-EC-042 clinical milestone. These earned PSUs vested the same day.
On May 14, 2026, Paulson sold 2,203 shares of common stock at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on June 10, 2021. The footnote states this sale was solely to satisfy withholding tax obligations from the PSU vesting and was not a discretionary trade. After these transactions, he directly held 269,747 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported a small automatic share sale tied to a performance-based equity award. On May 13, 2026, he acquired 700 shares of common stock via earned performance-based restricted stock units (PSUs) granted in February 2024, after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified as achieved.
On May 14, 2026, 266 shares of common stock were sold at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on May 16, 2022, solely to cover withholding tax liability from the PSU vesting. Following these transactions, Michael directly owns 94,398 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. Schedule 13G disclosure: Acorn-affiliated investment vehicles and Anders Hove report combined beneficial ownership positions in the issuer's common stock.
Acorn Bioventures, L.P. reports 637,608 shares (2.8%); Acorn Bioventures 2, L.P. reports 880,505 shares (3.9%); Anders Hove reports 1,518,113 shares (6.7%). The percentages are calculated using 22,662,943 shares outstanding as of May 7, 2026. Signatures are dated 05/15/2026.
Karyopharm Therapeutics Inc. ownership update: Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of 2,073,517 shares of Common Stock as of March 31, 2026. This holding represents 8.6% of the outstanding common shares, based on 24,116,833 shares outstanding as of March 30, 2026. The reported total includes 1,573,517 shares issuable upon exercise of warrants, which are subject to a 9.99% Beneficial Ownership Limitation.
Karyopharm Therapeutics reported a Q1 2026 net loss of $22.4 million on total revenue of $35.1 million, up from $30.0 million a year earlier. Product revenue from XPOVIO rose to $29.2 million, while license and other revenue declined to $5.9 million.
The company ended the quarter with $90.9 million in cash and cash equivalents and total assets of $131.4 million against total liabilities of $397.1 million, leaving a stockholders’ deficit of $265.6 million and an accumulated deficit of $1.8 billion.
Management concludes there is substantial doubt about the ability to continue as a going concern within one year, given ongoing losses, significant debt, required minimum liquidity covenants, and uncertainty around new funding or strategic alternatives. Recent financing included $26.9 million from a private placement and $19.8 million from at-the-market share sales, plus amendments and forbearance on term loan and convertible notes.
Karyopharm Therapeutics reported first quarter 2026 results with total revenue of $35.1 million, up from $30.0 million a year earlier. U.S. XPOVIO net product revenue rose to $29.2 million from $21.1 million, helped by lower gross-to-net adjustments, while royalty revenue increased to $1.9 million.
Operating loss improved to $26.8 million and net loss narrowed to $22.4 million, or $1.02 per basic share. The company reaffirmed 2026 total revenue guidance of $130–$150 million and U.S. XPOVIO revenue of $115–$130 million, and expects its cash to fund operations into late in the third quarter of 2026.
Karyopharm highlighted clinical milestones, including completion of enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial and positive Phase 3 SENTRY myelofibrosis results that met the spleen volume reduction endpoint but not the symptom score endpoint. Topline data readouts from multiple Phase 3 trials are expected in mid to second half of 2026.